Our discovery engine was built on the pioneering research of our co founders, Professors Siddharthan Chandran and Neil Carragher (University of Edinburgh, UK). Financial backing has been provided by two leading life sciences investors.
Based in Edinburgh and positioned to deploy the University’s world-leading expertise in phenotypic screening, stem cell technology and myelin biology, we aim to discover and develop small molecule therapeutics that promote remyelination for a variety of unmet medical needs.
We aim to develop an effective remyelination therapeutic which can be added onto current immune modulator drugs to deliver neuroprotection leading to arrest or slowing down of neurological disease progression and long term disability.Find Out More
Our visions is to mine and harness the power of human oligodendrocyte biology to deliver world leading neurotherapeutics that transform the lives of patients with disabling neurological disease.